DUBLIN--(BUSINESS WIRE)--The "Bioavailability Enhancement Technologies and Services Market, 2018-2030" report has been added to ResearchAndMarkets.com's offering.
This report provides a comprehensive study on the current scenario of technologies and contract services related to bioavailability enhancement.
The study features an elaborate discussion on the novel approaches adopted by different players offering solutions for altering the bioavailability of various drugs.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as likely number of candidates in BCS II and IV, likely adoption rates of bioavailability enhancement approaches, expected trend in outsourcing and likely pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030.
To account for the uncertainties associated with the expected future demand and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.
Key Topics Covered:
2. Executive Summary
4. Market Overview
5. Company Profiles
6. Benchmark Analysis
7. Partnerships And Collaborations
8. Publication Analysis
9. Patent Analysis
10. Clinical Trials Analysis
11. Demand Analysis
12. Market Forecast
14. Transcripts Of Public Discussions
15. Appendix 1: Tabular Data
16. Appendix 2: List Of Companies
- Ascendia Pharmaceuticals
- Particle Sciences (Acquired by Lubrizol)
- Juniper Pharma Services
- Kuecept (Acquired by Aptuit / Evotec)
- Creative Biolabs
- WuXi AppTec
For more information about this report visit https://www.researchandmarkets.com/research/3fds59/bioavailability?w=4